Table 1.
The comparisons of clinical characteristics between non-metastasis and metastasis group according to first disease metastasis
| Characteristics | Non-metastasis (n=39)
|
First disease metastasis (n=34)
|
|||||
|---|---|---|---|---|---|---|---|
| Bone (n=13)
|
Lung (n=13)
|
Liver (n=8)
|
|||||
| n (%) | n (%) | P-valuea | n (%) | P-valuea | n (%) | P-valuea | |
| Age at diagnosis; years | 0.110 | 1.000 | 1.000 | ||||
| ≤50 | 19 (48.7) | 10 (76.9) | 7 (53.9) | 4 (50.0) | |||
| >50 | 20 (51.3) | 3 (23.1) | 6 (46.1) | 4 (50.0) | |||
| Menstrual status | 0.099 | 0.523 | 1.000 | ||||
| Pre-menopause | 22 (56.4) | 11 (84.6) | 9 (69.2) | 5 (62.5) | |||
| Post-menopause | 17 (43.6) | 2 (15.4) | 4 (30.8) | 3 (37.5) | |||
| Tumor size; cm | 0.632 | 0.033* | 0.084 | ||||
| ≤5 | 35 (89.7) | 11 (84.6) | 8 (61.5) | 5 (62.5) | |||
| >5 | 4 (10.3) | 2 (15.4) | 5 (38.5) | 3 (37.5) | |||
| Lymph node status | 0.518 | 0.198 | 0.437 | ||||
| Positive | 21 (53.9) | 9 (69.2) | 10 (76.9) | 6 (75.0) | |||
| Negative | 18 (46.1) | 4 (30.8) | 3 (23.1) | 2 (25.0) | |||
| Tumor grading | 0.640 | 0.150 | 1.000 | ||||
| 1 | 6 (26.1) | 1 (11.1) | 0 (0.0) | 1 (16.7) | |||
| 2+3 | 17 (73.9) | 8 (88.9) | 9 (100.0) | 5 (83.3) | |||
| Unknownb | 16 (–) | 4 (–) | 4 (–) | 2 (–) | |||
| LVIc | 0.495 | 0.717 | 0.659 | ||||
| Positive | 13 (50.0) | 4 (36.4) | 4 (40.0) | 2 (33.3) | |||
| Negative | 13 (50.0) | 7 (63.6) | 6 (60.0) | 4 (66.7) | |||
| Unknownb | 13 (–) | 2 (–) | 3 (–) | 2 (–) | |||
| ER and/or PR status | n/a | n/a | n/a | ||||
| Positive | 39 (100.0) | 13 (100.0) | 13 (100.0) | 8 (100.0) | |||
| Negative | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
Notes:
a
Fisher’s exact test;
b
unknown statuses were excluded from Fisher’s exact test;
c
LVI (lymphovascular invasion) is considered as spreading of cancer to blood vessels and/or lymphatic system.
*
Statistically significant at P-value <0.05.
Abbreviations: ER, estrogen receptor; n/a, not applicable; PR, progesterone receptor.